MediciNova, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel small-molecule therapeutics for neurodegenerative, inflammatory, fibrotic and oncological diseases. Founded in the late 1990s, the company advances its proprietary compounds through clinical trials and strategic partnerships, with a goal of addressing areas of high unmet medical need. MediciNova is headquartered in San Diego, California, and maintains a presence in Tokyo to support collaborations and regulatory interactions in Asian markets.
The company’s leading clinical asset, MN-166 (ibudilast), is an anti-inflammatory and neuroprotective agent originally approved in Japan for asthma and post-stroke dizziness. MediciNova is evaluating ibudilast in multiple late-stage and exploratory studies, including progressive multiple sclerosis, amyotrophic lateral sclerosis (ALS) and substance use disorders such as opioid and alcohol dependence. Ibudilast’s mechanism of action involves modulation of glial cell activity in the central nervous system, aiming to slow neurodegeneration and reduce inflammation.
Another key compound, MN-001 (tipelukast), is a leukotriene receptor antagonist in development for idiopathic pulmonary fibrosis (IPF), nonalcoholic steatohepatitis (NASH) and diabetic nephropathy. MN-001 has completed Phase II trials in IPF patients and is being positioned as a potential treatment for a range of progressive fibrotic conditions. MediciNova also maintains a preclinical respiratory portfolio, including β1-adrenergic agonists aimed at acute lung injury and chronic obstructive pulmonary disease (COPD).
MediciNova leverages partnerships with pharmaceutical companies in Japan and globally to support late-stage trials and potential commercialization. The company’s multidisciplinary leadership team brings together expertise in clinical development, regulatory affairs and global business development to advance its pipeline. Through a combination of in-house research and strategic alliances, MediciNova seeks to deliver new therapies across multiple therapeutic areas with significant market opportunities.
AI Generated. May Contain Errors.
